3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 3
2
Phase 1
2
Phase 1/2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Graft vs Host Disease
3
Tuberous Sclerosis
2
Skin Neoplasms
2
Myelodysplastic Syndromes
2
Lymphangioleiomyomatosis
2
Leukemia, Myeloid, Acute
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Hodgkin Disease
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Waldenstrom Macroglobulinemia
1
Urinary Bladder Neoplasms
1
Rhabdomyosarcoma, Embryonal
1
Rhabdomyosarcoma, Alveolar
1
Rhabdomyosarcoma
1
PRETEXT I Hepatoblastoma
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, Prolymphocytic, T-Cell
1
Leukemia, Prolymphocytic
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Epilepsy
1
Drug Resistant Epilepsy
1
Carcinoma, Squamous Cell
1
Bronchiolitis Obliterans Syndrome
1
Interventions
Sirolimus
2
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphangioleiomyomatosis
×
Sirolimus
×
Clear all
NCT03150914
2024-12-24
MILED
University of Cincinnati
Phase 3
Active not recruiting
60 enrolled
NCT00414648
2023-11-02
MILES
University of Cincinnati
Phase 3
Completed
89 enrolled
15 charts